Firms
Theme

PMVP

PMV Pharmaceuticals, Inc · NASDAQ

↓ $0.04 (2.68%)

Last close · Oct 23, 4:00 PM ET

Sign up free to see this.

Mkt Cap
$67.9M
Volume
167.2K
52W High
$1.91
52W Low
$1.02
PE Ratio
—
Avg Vol
762.5K
As of 10/23/26
Div Yield
—
Beta
0.76
As of 10/23/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about PMVP?

Latest news

News ›

Zacks Investment Research

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $PMVP · 0 threads

Sign in to post on $PMVP

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev